CompletedNot Applicable

Leveraging Plasma Concentration Levels to Optimize Extracorporeal Treatment in Acute Diquat Poisoning

China163 participantsStarted 2022-02-01

Plain-language summary

This study aimed to evaluate the clinical value of plasma diquat concentration in guiding personalized extracorporeal treatment regimens for patients with acute diquat poisoning.

Who can participate

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. history of oral exposure to diquat solution reported by patient or proxy;
. a specimen for the plasma diquat concentration collected immediately upon admission;
. documentation that patients or, in case of unconsciousness of the patient, legal proxies were aware of and agreed to treatment plans.
. they had ingested other toxins in addition to diquat (qualitative toxicological screening tests);
. diquat was not detected in specimens, or plasma concentration data were unavailable;
. patients with an exposure time (time from exposure to presentation) longer than 48 hours;
. patients had ECTR prior to ED presentation.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

28-day survival

Timeframe: 28 days from the index date

Time from exposure to death

Timeframe: 28 days from the index date

Trial details

NCT IDNCT06807151

SponsorThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-07-31

View on ClinicalTrials.gov More Diquat Poisoning trials

Who can participate

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. history of oral exposure to diquat solution reported by patient or proxy;
. a specimen for the plasma diquat concentration collected immediately upon admission;
. documentation that patients or, in case of unconsciousness of the patient, legal proxies were aware of and agreed to treatment plans.
. they had ingested other toxins in addition to diquat (qualitative toxicological screening tests);
. diquat was not detected in specimens, or plasma concentration data were unavailable;
. patients with an exposure time (time from exposure to presentation) longer than 48 hours;
. patients had ECTR prior to ED presentation.